Corvus Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Amortized Cost
Corvus Pharmaceuticals, Inc. (CRVS) had Debt Securities, Available-for-sale, Amortized Cost of $62.76 million as of 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-11-04
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $62.76M.
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $59.68M.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $39.16M.
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $43.14M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2025-09-30 | $62.76M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $59.68M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $39.16M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $43.14M 10-Q · filed 2025-11-04 |
| 2024-09-30 | $36.81M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $32.40M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $14.67M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $14.51M 10-K · filed 2025-03-25 |
| 2023-09-30 | $12.07M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $29.37M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $24.82M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $29.20M 10-K · filed 2024-03-19 |
| 2022-09-30 | $25.11M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $28.33M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $31.51M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $6.00M 10-K · filed 2023-03-28 |
| 2021-09-30 | $4.03M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $7.54M 10-Q · filed 2021-08-02 |
| 2021-03-31 | $22.86M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $27.80M 10-K · filed 2022-03-10 |
| 2020-09-30 | $28.37M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $38.50M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $45.17M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $72.80M 10-K · filed 2021-03-25 |
| 2019-09-30 | $77.32M 10-Q · filed 2019-10-29 |
| 2019-06-30 | $66.62M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $66.82M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $75.44M 10-K · filed 2020-03-09 |
| 2018-09-30 | $81.93M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $105.18M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $41.41M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $44.99M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |